Innate Pharma

France - MarseillePharmaceutical1 H-1B visas (FY2023)

Focus: Innate Pharma is a French oncology-focused biopharmaceutical company specializing in monoclonal antibodies and immunotherapy. The company operates as a mid-cap biotech with a marketed product (LUMOXITI) and an extensive clinical pipeline primarily in hematologic and solid tumors.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Innate Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Innate Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

LUMOXITI

Refractory hairy cell leukemia (HCL) after prior purine nucleoside analog treatment

Peak

CD22-directed cytotoxin approved for a niche hematologic indication; represents company's only marketed revenue driver and proof-of-concept for antibody-toxin conjugate platform.

Products & Portfolio (1)

Help build intelligence for Innate Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

product: Innea Aqua vaginal use

Vulvo Vaginal Atrophy

N/A

Clinical Trials (1)

NCT07367061Clinical Investigation to Assess Safety and Efficacy of INNEA AQUA in Adult Women With Vulvo-Vaginal Atrophy (VVA)

N/A

Raw turmeric shots

Turmeric

N/A

Clinical Trials (1)

NCT07196514Effects of 8 Weeks of Turmeric Ingestion on Physiology and Wellbeing in Healthy Older Adults

N/A

immunohistochemistry assay

Solid Cancer

N/A

Clinical Trials (1)

NCT03311100Immunological Profile of Solid Tumors Sample

N/A

Promovia Hydro Balance 100 mg, Hyaluronic acid sodium salt and trehalose

Meniscus Tears

N/A

Clinical Trials (1)

NCT07539194Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears

N/A

Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fun

Bacterial Infections

N/A

Clinical Trials (1)

NCT07367295Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial Infections

N/A

draw blood

COVID-19

N/A

Clinical Trials (1)

NCT04369820C5a Receptor Expression - COVID-19 (C5-COV)

N/A

Innea, Innea Aqua

Wrinkle

N/A

Clinical Trials (1)

NCT07331181Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles

N/A

Study of the Immune Response in Colon Adenocarcinoma

Colon Adenocarcinoma

N/A

Clinical Trials (1)

NCT03015038Study of the Immune Response in Colon Adenocarcinoma

N/A

Water

Dehydration

N/A

Clinical Trials (1)

NCT07468539Post-exercise Rehydration: A Randomised Cross-over Trial Comparing a 100% Fruit Beverage, a Glucose-based Sports Drink, and Water

N/A

lacutamab

Peripheral T Cell Lymphoma

Phase 1

Clinical Trials (1)

NCT05321147Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Phase 1

IPH2101 combined to lenalidomide

Patients With Multiple Myeloma Experiencing a

Phase 1

Clinical Trials (1)

NCT01217203Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Phase 1

IPH2101

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT01256073A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

Phase 1

IPH5401 and Durvalumab

Advanced Solid Tumors

Phase 1

T gamma delta lymphocytes

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT00562666Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells

Phase 1

Anti-KIR

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT00552396An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma

Phase 1

IPH4102

Cutaneous T-Cell Lymphoma

Phase 1

Clinical Trials (1)

NCT02593045Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Phase 1

NNC 0141-0000-0100

Inflammation

Phase 1

Clinical Trials (1)

NCT01370902Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Phase 1

IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB

Metastatic Cancer

Phase 1

Clinical Trials (1)

NCT05143970A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Phase 1

Monalizumab

Hematologic Malignancies

Phase 1

Clinical Trials (1)

NCT02921685Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation

Phase 1

IPH2201

Gynecologic Cancer

Phase 1

Clinical Trials (1)

NCT02459301A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies